ImmuneWorks is a clinical stage biotechnology company with deep expertise in immunology and lung disease. The Company, based in Indianapolis, was founded in 2006, receiving an exclusive license from Indiana University. ImmuneWorks is developing IW001, using an immune modulation approach to treat idiopathic pulmonary fibrosis ("IPF"), an orphan disease indication with significant unmet medical need. ImmuneWorks has completed a Phase 1 trial in IPF patients, which demonstrated safety and evidence of clinical efficacy via oral administration of IW001.
Looking for a particular ImmuneWorks, Inc. employee's phone or email?
The ImmuneWorks, Inc. annual revenue was $3 million in 2026.
ImmuneWorks, Inc. is based in Indianapolis, Indiana.
The NAICS codes for ImmuneWorks, Inc. are [325, 32, 32541, 3254].
The SIC codes for ImmuneWorks, Inc. are [28, 283].